<DOC>
	<DOCNO>NCT00126269</DOCNO>
	<brief_summary>This randomized phase III trial compare cisplatin without gemcitabine patient carcinoma unknown primary predict favorable prognosis . The purpose trial compare overall survival rate patient carcinoma unknown primary ( CUP ) predict favorable prognosis accord French classification treat cisplatin without gemcitabine .</brief_summary>
	<brief_title>Trial Comparing Cisplatin With Without Gemcitabine Patients With Carcinoma Unknown Primary</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms , Unknown Primary</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Patients older 18 year Evidence CUP base histologic examination Negative search primary tumor site use recommend guideline Disease classify good prognosis accord French classification criterion : *performance status &gt; 2 *normal serum LDH No prior chemotherapy No previous carcinoma , except basalcell carcinoma skin Adequate renal function : measure calculated creatinine clearance &gt; 60 ml/min Absolute granulocyte count ≥ 1,500/mm3 ; platelet ≥ 100,000 mm3 ; bilirubin ≤ 1.5 fold upper normal value Signed informed consent Patients infected Human Immunodeficiency Virus ( HIV ) CUP belong one follow subgroup : 1 ) Axillary lymph node adenocarcinoma woman ; 2 ) Serous adenocarcinoma peritoneum woman ; 3 ) Undifferentiated carcinoma middle line young man ; 4 ) Squamouscell carcinoma ; 5 ) Neuroendocrine carcinoma ; 6 ) Bone metastasis elevate serum prostate specific antigen ( PSA ) man Patients fit inclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Patients Carcinoma Unknown Primary Predicted Favorable Prognosis</keyword>
</DOC>